Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Molecular Partners

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Announces Pricing of $20 Million Underwritten Offering
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Reports H1 2024 Corporate Highlights and Financials
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Life Science Cares Launches in Switzerland
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Publishes Invitation to Annual General Meeting 2024
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Announces Dismissal of Class Action Lawsuit
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.